Supporting Information for

BF₃•OEt₂-Mediated Transamidation of Unprotected Primary

Amides Under Solvent-free condition

Qing-Wen Gui,^a Shengneng Ying,^a Xin Liu,^a Jianfang Wang,^b Xuliang

Xiao,^a Zhuoliang Liu*,^b Xia Wang*,^a Yanxue Shang,^a and Qiang Li^c

^{*a.*} College of Chemistry and Materials Science, Hunan Agricultural University,

Changsha, 410128, PR China. E-mail: wangxia@hunau.edu.cn

^{b.} College of Science, National University of Defense Technology, Changsha 410128,

P. R. China; Email: hemazaizai@163.com

^{*c*} College of Agronomy, Hunan Agricultural University, Changsha 410128, P. R. China

Table of Content

1.	General Information	S2
2.	Experimental Section	S2
3.	Optimize Reaction Conditions	S4
4.	Characterization data of products	S 7
5.	¹ H and ¹³ C NMR spectra of products	S24
6.	References	S90

1. General Information

All glassware was oven dried at 60 °C for 8 hours and cooled down under vacuum. Unless otherwise noted, all reagents were purchased from commercial suppliers and used without further purification. Analytical thin layer chromatography (TLC) was performed on precoated aluminum-backed silica gel 60 F₂₅₄ plates (EMD Millipore, 200 µm thickness). TLC plates were visualized with ultraviolet light. Flash column chromatography was performed using Tsingtao silica gel (200-300). ¹H, ¹³C and ¹⁹F NMR spectra were recorded on a Bruker Avance DRX - 400 spectrometers; chemical shifts (δ) are given in ppm and calibrated using the signal of residual undeuterated solvent as internal reference (CDCl₃: δ H = 7.26 ppm and δ C = 77.16 ppm, DMSO-*d*₆: δ H = 2.50 ppm and δ C = 39.50 ppm). Data for ¹H NMR, ¹⁹F NMR and ¹³C NMR are reported as follows: chemical shift (δ , ppm), multiplicity, integration, and coupling constant (Hz).

2. Experimental Section

General experimental procedures for 3a



Para-toluamide **1** (1.0 eq, 0.50 mmol, 67.60 mg), n-butylamine **2** (2.0 eq, 1.00 mmol, 73.10 mg) and BF₃•OEt₂ (1.0 eq, 0.50 mmol, 70.90 mg) were added separately to a dry reaction tube (10 mL) with magnetic stirrer, without adding additional solvent. The reaction was carried out in 100 °C oil bath for 16 h. After the reaction completed, the reaction solution was diluted with DCM, filtered by silica gel short column, and washed by DCM. The crude mixture is concentrated in vacuum, the crude mixture is concentrated in vacuum, the crude mixture is concentrated in vacuum, and the obtained crude product is purified by silica gel flash chromatography. Eluted product **3a** with a mixture of ethyl acetate, petroleum ether and methylene chloride (1:16:5), and the yield was 96% (99.50 mg).

General experimental procedures for 3d



Para-toluamide **1** (1.0 eq, 0.50 mmol, 67.60 mg), aniline **2** (1.5 eq, 0.75 mmol, 69.80 mg) and BF₃•OEt₂ (1.0 eq, 0.50 mmol, 70.90 mg) were added separately to a dry reaction tube (10 mL) with magnetic stirrer, without adding additional solvent. The reaction was carried out in 100 °C oil bath for 16 h. After the reaction completed, the reaction solution was diluted with DCM, filtered by silica gel short column, and washed by DCM. The crude mixture is concentrated in vacuum, the crude mixture is concentrated in vacuum, the crude mixture is concentrated in vacuum, and the obtained crude product is purified by silica gel flash chromatography. Eluted product **3d** with a mixture of ethyl acetate, petroleum ether and methylene chloride (1:16:5), and the yield was 92% (97.20 mg).

3. Optimize Reaction Conditions

We started with 4-methylbenzamide **1a** and ^{*n*}Bu-NH₂ **2a** as model substrates to investigate the transamidation reaction. In order to optimize the reaction conditions, we set a series of experimental parameters, including the boron lewis acids, dosage of BF_3 •OEt₂, solvent and reaction time.

Table S1	Op	timization	of Boron	ı L	ewis	acids

N	H ₂ + "Bu-NH ₂	Boron Lewi solvent-fre	s acids (1.0 eq.) ≫ e, 100 °C, 16 h	N ^{#Bu} H
1a , 1.0 eq	2a , 2.0 eq			3a
Entry	Lewis acids	Tem. (°C)	Solvent	Yield (%) ^ö
1	HBF_4 (48 wt.% in $H_2O)$	100	-	89
2	BCl ₃ (1 M in PhMe)	100	-	55
3	BBr ₃	100	-	47
4	$B(C_6F_5)_3$	100	-	48
5	$BF_3ulletOEt_2$	100	-	96

Table S2 Optimization of BF3•OEt2 dosage

NH ₂	+ ⁿ Bu-NH ₂	BF ₃ • OEt ₂ (0.1-1.0 eq) solvent-free, 100 °C, 16 h		. N ^{°Bu}	
1a , 1.0 eq	2a , 2.0 eq			3a	
Entry	Lewis acid (eq)	Tem. (°C)	Solvent	Yield (%) ^b	
1	0.1(10 mol%)	100	-	44	
2	0.2	100	-	60	
3	0.5	100	-	67	
4	0.8	100	-	81	
5	1.0	100	-	96	

NH ₂	+ ["] Bu—	NH ₂ BF ₃ - solvent-fi	•OEt ₂ (1.0 eq) ree, 100 °C, Time	N ² Bu
1a , 1.0 eq	2a , 2.	0 eq		3a
Entry	Lewis acid	Tem. (°C)	Time (h)	Yield (%) ^b
1	BF ₃ ∙OEt ₂	100	4	57
2	$BF_3 ullet OEt_2$	100	8	73
3	BF ₃ ∙OEt ₂	100	12	88
4	BF ₃ ∙OEt ₂	100	16	96

Table S3 Optimization of reaction time

Table S4 Optimization of Solvents

NH:	, + [″] Bu−N⊦	BF ₃ •O	BF ₃ •OEt ₂ (1.0 eq)		
1 a, 1.0 eq	2a , 2.0 c	eq		3a	
Entry	Solvent	Tem. (°C)	Time (h)	Yield (%) ⁶	
1	THF	100	16	41	
2	DMF	100	16	35	
3	DMSO	100	16	31	
4	Toluene	100	16	88	
5	2-MeTHF	100	16	39	
6	1,4-Dioxane	100	16	47	
7		100	16	96	

Figure S1 Radical Capture Experiments



4. Characterization data of products

N-butyl-4-methylbenzamide $(3a)^1$



3a was obtained in 96% yield (99.50 mg) as a white oil;

¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.2 Hz, 2H), 7.17 (d, *J* = 8.2 Hz, 2H), 6.50 (s, 1H), 3.39 (q, *J* = 7.2, 6.8 Hz, 2H), 2.35 (s, 3H), 1.55 (t, *J* = 7.4 Hz, 2H), 1.36 (q, *J* = 7.4 Hz, 2H), 0.91 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 167.7, 141.6, 132.0, 129.1, 126.9, 39.8, 31.8, 21.4, 20.2, 13.8. MS:m/z 207 (M⁺).

N-cyclopentyl-4-methylbenzamide $(3b)^2$



3b was obtained in 90% yield (91.50 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 7.9 Hz, 2H), 7.18 (d, *J* = 7.7 Hz, 2H), 6.22 (s, 1H), 4.36 (q, *J* = 7.1 Hz, 1H), 2.36 (s, 3H), 2.12 – 1.97 (m, 2H), 1.75 – 1.55 (m, 4H), 1.54 – 1.37 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 167.2, 141.6, 132.0, 129.2, 126.9, 51.7, 33.2, 23.9, 21.5. MS:m/z 203 (M⁺).

N-cyclohexyl-4-methylbenzamide $(3c)^3$



3c was obtained in 92% yield (99.90 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 7.8 Hz, 2H), 7.17 (d, *J* = 7.8 Hz, 2H), 6.17 (s, 1H), 3.93 (s, 1H), 2.35 (s, 3H), 1.98 (d, *J* = 16.6 Hz, 2H), 1.71 (d, *J* = 13.9 Hz, 2H), 1.66 – 1.55 (m, 1H), 1.37 (q, *J* = 13.0, 12.6 Hz, 2H), 1.28 – 1.11 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 166.7, 141.5, 132.3, 129.1, 126.9, 48.7, 33.2, 25.6, 25.0, 21.5. MS:m/z 217 (M⁺).

4-methyl-N-phenylbenzamide $(3d)^4$



3d was obtained in 92% yield (97.10 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃): δ 8.09 (s, 1H), 7.75 (d, *J* = 7.8 Hz, 2H), 7.64 (d, *J* = 8.0 Hz, 2H), 7.33 (t, *J* = 7.7 Hz, 2H), 7.22 (d, *J* = 7.8 Hz, 2H), 7.13 (t, *J* = 7.5 Hz, 1H), 2.40 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 166.0, 142.4, 138.2, 132.2, 129.4, 129.1, 127.2, 124.5, 120.4, 21.6.

MS:m/z 211 (M⁺).

4-methyl-N-(p-tolyl)benzamide $(3e)^5$



3e was obtained in 94% yield (105.80 mg) as a white solid;

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.09 (s, 1H), 7.87 (d, *J* = 8.2 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 7.9 Hz, 2H), 7.14 (d, *J* = 8.2 Hz, 2H), 2.38 (s, 3H), 2.27 (s, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.1, 141.4, 136.7, 132.5, 132.2, 128.9, 128.9, 127.6, 120.4, 21.0, 20.5.

MS:m/z 225 (M⁺).

4-methyl-N-(m-tolyl)benzamide $(3f)^6$



3f was obtained in 89% yield (100.10 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 7.76 (d, *J* = 7.9 Hz, 2H), 7.52 (s, 1H), 7.47 (d, *J* = 8.3 Hz, 1H), 7.19 (d, *J* = 7.8 Hz, 1H), 7.15 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 7.6 Hz, 1H), 2.37 (s, 3H), 2.29 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 166.2, 142.0, 138.7, 138.1, 132.1, 129.2, 128.6, 127.2, 125.1, 121.2, 117.7, 21.4, 21.4.

MS:m/z 225 (M⁺).

N-(3,5-dimethylphenyl)-4-methylbenzamide (3g)⁶



3g was obtained in 88% yield (105.10 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.27 (s, 2H), 7.24 (d, *J* = 8.0 Hz, 2H), 6.77 (s, 1H), 2.40 (s, 3H), 2.29 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 165.7, 142.3, 138.8, 138.0, 132.4, 129.5, 127.1, 126.3, 118.1, 21.6, 21.5.

MS:m/z 239 (M⁺).

 $N-(4-(tert-butyl)phenyl)-4-methylbenzamide (3h)^7$

3h was obtained in 91% yield (121.50 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H), 7.75 (d, *J* = 7.9 Hz, 2H), 7.55 (d, *J* = 8.6 Hz, 2H), 7.36 (d, *J* = 8.5 Hz, 2H), 7.24 (d, *J* = 7.7 Hz, 2H), 2.40 (s, 3H), 1.31 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 165.8, 147.5, 142.3, 135.6, 132.4, 129.5, 127.2, 126.0, 120.2, 34.5, 31.5, 21.6.

MS:m/z 267 (M⁺).

 $N-(2,6-dimethylphenyl)-4-methylbenzamide (3i)^8$



3i was obtained in 83% yield (99.20 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.9 Hz, 2H), 7.51 (s, 1H), 7.25 (d, *J* = 7.6 Hz, 2H), 7.11 (d, *J* = 5.1 Hz, 1H), 7.09 (d, *J* = 5.3 Hz, 2H), 2.42 (s, 3H), 2.23 (s, 6H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 165.9, 142.3, 135.7, 134.2, 131.7, 129.5, 128.3, 127.4, 127.4, 21.6,

18.6.

MS:m/z 239 (M⁺).

 $N-(2-methoxyphenyl)-4-methylbenzamide (3j)^9$



3j was obtained in 89% yield (107.20 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 7.4 Hz, 2H), 7.80 (d, *J* = 7.9 Hz, 2H), 7.29 (d, *J* = 7.9 Hz, 2H), 7.11 – 6.98 (m, 2H), 6.91 (d, *J* = 8.0 Hz, 1H), 3.91 (s, 3H), 2.42 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 165.3, 148.2, 142.2, 132.5, 129.5, 128.0, 127.1, 123.8, 121.2, 119.9, 110.0, 55.9, 21.6.

MS:m/z 241 (M⁺).

N-(4-(dimethylamino)phenyl)-4-methylbenzamide (3k)



3k was obtained in 79% yield (100.30 mg) as a white solid;

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.91 (s, 1H), 7.89 (d, *J* = 7.9 Hz, 2H), 7.60 (d, *J* = 8.6 Hz, 2H), 7.31 (d, *J* = 7.8 Hz, 2H), 6.73 (d, *J* = 8.8 Hz, 2H), 2.87 (s, 6H), 2.38 (s, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.5, 147.2, 141.0, 132.3, 128.9, 128.8, 127.5, 121.8, 112.4, 40.4, 20.9.

HRMS (ESI) m/z calcd. for $C_{16}H_{18}N_2O$ [M+H]⁺: 255.1492, found 255.1498.

 $N-(4-fluorophenyl)-4-methylbenzamide (3l)^{10}$



31 was obtained in 94% yield (107.60 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 10.22 (s, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 5.1 Hz, 1H), 7.79 (d, J = 5.1 Hz, 1H), 7.33 (d, J = 7.9 Hz, 2H), 7.18 (t, J = 8.9 Hz, 2H), 2.38 (s, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.3, 159.4, 157.0, 141.6, 135.6 (d, J = 2.5 Hz), 131.9, 128.9,

127.7, 122.2 (d, J = 7.8 Hz), 115.2, 115.0, 21.0.

¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -119.07.

 $MS:m/z \ 229 \ (M^{+}).$

N-(3-chlorophenyl)-4-methylbenzamide $(3m)^{11}$



3m was obtained in 87% yield (106.90 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1H), 7.74 (d, *J* = 6.9 Hz, 2H), 7.71 (s, 1H), 7.48 (d, *J* = 8.3 Hz, 1H), 7.22 (d, *J* = 8.0 Hz, 3H), 7.08 (d, *J* = 7.9 Hz, 1H), 2.39 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 166.1, 142.7, 139.4, 134.7, 131.7, 130.0, 129.5, 127.2, 124.5, 120.5,

118.4, 21.6.

MS:m/z 245 (M⁺).

4-methyl-N-(perfluorophenyl)benzamide $(3n)^{12}$



3n was obtained in 81% yield (122.00 mg) as a yellow solid;

¹H NMR (400 MHz, DMSO- d_6) δ 10.44 (s, 1H), 7.91 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 2.40 (s, 3H).

¹³CNMR (100 MHz, DMSO-d₆) δ 165.3, 147.2 – 142.8 (m), 142.7, 141.7 – 136.1 (m), 129.5, 129.2, 128.0, 113.6 – 113.1(m), 21.1

¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -140.54, -152.72, -158.68.

MS:m/z 301 (M⁺).

N,4-dimethyl-N-phenylbenzamide $(3o)^{13}$

30 was obtained in 87% yield (98.00 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.22 – 7.13 (m, 4H), 7.12 – 7.04 (m, 1H), 7.00 (d, *J* = 7.9 Hz, 2H), 6.91 (d, *J* = 7.8 Hz, 2H), 3.45 (s, 3H), 2.19 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 170.5, 145.0, 139.7, 132.8, 129.0, 128.8, 128.3, 126.7, 126.3, 38.4, 21.3.

MS:m/z 225 (M⁺).

N-ethyl-4-methyl-N-phenylbenzamide $(3p)^{14}$



3p was obtained in 77% yield (92.10 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.15 (m, 4H), 7.17 – 7.08 (m, 1H), 7.02 (d, *J* = 7.7 Hz, 2H), 6.93 (d, *J* = 7.9 Hz, 2H), 3.97 (q, *J* = 7.1 Hz, 2H), 2.22 (s, 3H), 1.21 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 170.2, 143.6, 139.6, 133.4, 129.1, 128.9, 128.4, 127.9, 126.5, 45.5, 21.4, 13.0.

MS:m/z 239 (M⁺).

(3,4-dihydroquinolin-1(2H)-yl)(p-tolyl)methanone (3q)¹⁵



3q was obtained in 57% yield (71.60 mg) as a white solid;

¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 7.7 Hz, 2H), 7.04 (d, *J* = 7.5 Hz, 1H), 6.96 (d, *J* = 7.8 Hz, 2H), 6.88 (t, *J* = 7.5 Hz, 1H), 6.76 (t, *J* = 7.8 Hz, 1H), 6.63 (d, *J* = 8.1 Hz, 1H), 3.80 (t, *J* = 6.5 Hz, 2H), 2.73 (t, *J* = 6.6 Hz, 2H), 2.22 (s, 3H), 1.93 (t, *J* = 6.6 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 170.3, 140.3, 139.5, 133.3, 131.5, 128.7, 128.7, 128.3, 125.7, 125.4, 124.4, 44.4, 26.9, 24.2, 21.4.

 $MS:m/z \ 251 \ (M^+).$

N,N-diethyl-4-methylbenzamide $(3r)^{13}$

3r was obtained in 53% yield (50.60 mg) as a white oil;

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.22 (s, 4H), 3.40 (s, 2H), 3.18 (s, 2H), 2.32 (s, 3H), 1.24 – 0.90 (m, 6H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 170.2, 138.6, 134.5, 128.9, 126.2, 42.9, 38.9, 20.9, 14.1, 12.9. MS:m/z 191 (M⁺).

N, N-diisopropyl-4-methylbenzamide $(3s)^{16}$

3s was obtained in 44% yield (48.30 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 7.21 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 3.62 (s, 2H), 2.31

(s, 3H), 1.26 (m, 12H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 170.0, 138.0, 136.2, 129.0, 125.4, 20.9, 20.4.

 $MS:m/z \ 219 \ (M^+).$

N,N-dibenzyl-4-methylbenzamide $(3t)^{17}$



3t was obtained in 51% yield (80.40 mg) as a white solid;

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.41 – 7.10 (m, 14H), 4.56 (s, 2H), 4.39 (s, 2H), 2.29 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.5, 139.3, 136.7, 133.3, 129.1, 128.8, 127.6, 126.8, 126.6, 51.5, 46.9, 20.9.

MS:m/z 315 (M⁺). Morpholino(p-tolyl)methanone (3u)¹⁸



3u was obtained in 60% yield (61.50 mg) as a white oil;

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.30 (d, *J* = 8.2 Hz, 2H), 7.24 (d, *J* = 7.9 Hz, 2H), 3.57 (s, 8H), 2.32 (s, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 169.3, 139.4, 132.7, 129.0, 127.2, 66.2, 21.0.

MS:m/z 205 (M⁺).

N-(p-tolyl)butyramide $(3v)^{19}$



3v was obtained in 81% yield (71.70 mg) as a white solid

¹H NMR (400 MHz, DMSO- d_6) δ 9.75 (s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 2.26 (d, J = 7.3 Hz, 2H), 2.23 (s, 3H), 1.60 (q, J = 7.3 Hz, 2H), 0.90 (t, J = 6.7 Hz, 3H). ¹³C NMR (100 MHz, DMSO- d_6) δ 170.8, 136.8, 131.7, 129.0, 119.0, 38.3, 20.4, 18.6, 13.6.

MS:m/z 177 (M⁺).

N-(3,5-dimethylphenyl)butyramide $(3w)^{20}$



3w was obtained in 90% yield (86.00 mg) as a yellow oil

¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 1H), 7.17 (s, 2H), 6.73 (s, 1H), 2.30 (t, *J* = 7.5 Hz, 2H), 2.25 (s, 6H), 1.73 (q, *J* = 7.4 Hz, 2H), 0.97 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 171.7, 138.6, 138.0, 125.9, 117.8, 39.7, 21.4, 19.2, 13.8.

MS:m/z 191 (M⁺).

 $N-(4-(tert-butyl)phenyl)butyramide (3x)^{21}$



3x was obtained in 94% yield (110.60 mg) as a yellow oil

¹H NMR (400 MHz, DMSO- d_6) δ 9.77 (s, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 2.24 (t, J = 7.3 Hz, 2H), 1.59 (q, J = 7.4 Hz, 2H), 1.21 (s, 9H), 0.88 (t, J = 7.4 Hz, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.1, 145.4, 136.8, 125.2, 119.1, 38.4, 34.0, 31.3, 18.8, 13.7. MS:m/z 235 (M⁺).

N-(2-methoxyphenyl) butyramide $(3y)^{22}$



3y was obtained in 93% yield (89.80 mg) as a yellow oil

¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 6.2 Hz, 1H), 7.70 (s, 1H), 6.91 (d, *J* = 7.4 Hz, 1H), 6.85 (d, *J* = 7.6 Hz, 1H), 6.75 (d, *J* = 7.8 Hz, 1H), 3.76 (s, 3H), 2.26 (t, *J* = 7.5 Hz, 2H), 1.65 (q, *J* = 7.4 Hz, 2H), 0.90 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 171.2, 147.7, 127.7, 123.5, 121.0, 119.7, 109.8, 55.6, 40.0, 19.1, 13.8. MS:m/z 193 (M⁺).

N-(3-methoxyphenyl)butyramide $(3z)^{23}$



3z was obtained in 90% yield (86.90 mg) as a yellow oil

¹H NMR (400 MHz, CDCl₃) δ 7.70 (s, 1H), 7.33 (s, 1H), 7.17 (t, *J* = 8.2 Hz, 1H), 6.98 (d, *J* = 7.9 Hz, 1H), 6.65 (d, *J* = 2.6 Hz, 1H), 3.76 (s, 3H), 2.32 (t, *J* = 7.5 Hz, 2H), 1.73 (q, *J* = 7.4 Hz, 2H), 0.97 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 171.8, 160.1, 139.4, 129.7, 112.0, 110.1, 105.5, 55.3, 39.71, 19.1, 13.8. MS:m/z 193 (M⁺).

N-(4-phenoxyphenyl)butyramide (3aa)²⁴



3aa was obtained in 77% yield (98.30 mg) as a white solid

¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.49 (d, *J* = 8.5 Hz, 2H), 7.30 (t, *J* = 7.8 Hz, 2H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.95 (t, *J* = 8.2 Hz, 4H), 2.33 (t, *J* = 7.5 Hz, 2H), 1.74 (q, *J* = 7.4 Hz, 2H), 0.98 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 171.9, 157.6, 153.3, 133.7, 129.8, 123.1, 121.9, 119.6, 118.4, 39.4, 19.2, 13.8.

MS:m/z 255 (M⁺).

 $N-(3-(trifluoromethyl)phenyl)butyramide (3ab)^{25}$



3ab was obtained in 83% yield (95.90 mg) as a white solid

¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H), 7.88 (s, 1H), 7.70 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.8 Hz, 1H), 7.31 (d, *J* = 7.9 Hz, 1H), 2.36 (t, *J* = 7.5 Hz, 2H), 1.73 (q, *J* = 7.4 Hz, 2H), 0.95 (t, *J* = 7.4 Hz, 3H).

 ^{13}C NMR (100 MHz, CDCl₃) δ 172.8, 138.8, 131.4, 131.1, 129.4, 125.3, 123.3, 122.6, 120.8 (d, J = 3.7 Hz), 117.0 (d, J = 3.9 Hz), 39.4, 19.1, 13.7.

¹⁹F NMR (376 MHz, CDCl₃) δ -62.83. MS:m/z 231 (M⁺).

N-(3-chlorophenyl)butyramide (3ac)²⁰



3ac was obtained in 83% yield (82.00 mg) as a yellow oil

¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 1H), 7.66 (s, 1H), 7.36 (d, *J* = 10.1 Hz, 1H), 7.17 (t, *J* = 8.1 Hz, 1H), 7.03 (d, *J* = 8.7 Hz, 1H), 2.33 (t, *J* = 7.5 Hz, 2H), 1.72 (q, *J* = 7.4 Hz, 2H), 0.96 (t, *J* = 7.4 Hz, 3H).

 ^{13}C NMR (100 MHz, CDCl₃) δ 172.3, 139.3, 134.5, 129.9, 124.2, 120.3, 118.2, 39.5, 19.2, 13.8. MS:m/z 197 (M^+).

N-(3-bromophenyl)butyramide (3ad)



3ad was obtained in 90% yield (108.90 mg) as a yellow oil

¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.79 (d, J = 2.6 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 2.33 (t, J = 7.4 Hz, 2H), 1.73 (q, J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 172.1, 139.4, 130.3, 127.2, 123.0, 123.0, 122.6, 118.5, 118.5, 39.6, 19.1, 13.8.

HRMS (ESI) m/z calcd. for $C_{10}H_{12}BrNO [M+H]^+$: 242.0175, found 242.0189.

N-(3,5-dichlorophenyl)butyramide (3ae)



3ae was obtained in 81% yield (94.00 mg) as a white solid

¹H NMR (400 MHz, CDCl₃) δ 7.78 (s, 1H), 7.48 (d, *J* = 1.8 Hz, 2H), 7.06 (s, 1H), 2.34 (t, *J* = 7.4 Hz, 2H), 1.74 (q, *J* = 7.4 Hz, 2H), 0.98 (t, *J* = 7.4 Hz, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 172.1, 139.9, 135.3, 124.2, 118.3, 39.6, 19.1, 13.8.

HRMS (ESI) m/z calcd. for $C_{10}H_{11}Cl_2NO \ [M+H]^+: 232.0290$, found 232.0295.

N-butylbenzamide (5a)²⁶

5a was obtained in 93% yield (82.40 mg) as a white oil;

¹H NMR (400 MHz,CDCl₃) δ 7.75 (d, *J* = 7.6 Hz, 2H), 7.45 (t, *J* = 7.3 Hz, 1H), 7.38 (t, *J* = 7.5 Hz, 2H), 6.45 (s, 1H), 3.42 (q, *J* = 6.7 Hz, 2H), 1.64 – 1.47 (m, 2H), 1.38 (q, *J* = 7.5 Hz, 2H), 0.92 (t, *J* = 7.3 Hz, 3H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 167.7, 134.9, 131.3, 128.5, 127.0, 39.9, 31.8, 20.2, 13.9.

MS:m/z 177 (M⁺).

4-(tert-butyl)-N-butylbenzamide (5b)²⁷

N H

5b was obtained in 93% yield (108.50 mg) as a white oil;

¹H NMR (400 MHz, DMSO- d_6) δ 8.35 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 3.25 (q, J = 6.6 Hz, 2H), 1.52 – 1.42 (m, 2H), 1.35 – 1.29 (m, 2H), 1.28 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, DMSO- d_6) δ 165.7, 153.6, 132.0, 127.0, 124.9, 38.8, 34.5, 31.3, 30.9, 19.7, 13.7. MS:m/z 233 (M⁺).

N-butyl-4-methoxybenzamide $(5c)^{27}$

5c was obtained in 93% yield (96.40 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.73 (d, *J* = 8.3 Hz, 2H), 6.95 (s, 1H), 6.79 (d, *J* = 8.4 Hz, 2H), 3.74 (s, 3H), 3.32 (q, *J* = 6.8 Hz, 2H), 1.50 (t, *J* = 7.6 Hz, 2H), 1.29 (q, *J* = 7.6 Hz, 2H), 0.84 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 167.3, 161.9, 128.8, 127.0, 113.5, 55.3, 39.8, 31.7, 20.1, 13.8. MS:m/z 207 (M⁺).

N-butyl-3,4,5-trimethoxybenzamide (5d)²⁸



5d was obtained in 88% yield (117.60 mg) as a white oil;

¹H NMR (400 MHz,CDCl₃) δ 7.06 (s, 2H), 6.95 (t, *J* = 5.8 Hz, 1H), 3.84 (s, 4H), 3.81 (s, 6H), 3.37 (q, *J* = 6.7 Hz, 2H), 1.54 (t, *J* = 7.5 Hz, 2H), 1.34 (q, *J* = 7.5 Hz, 2H), 0.89 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 167.2, 153.0, 140.5, 130.2, 104.4, 60.8, 56.1, 39.9, 31.7, 20.1, 13.7. MS:m/z 267 (M⁺).

N-butyl-4-chlorobenzamide (5e)²⁹



5e was obtained in 92% yield (97.40 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 8.51 (t, J = 5.6 Hz, 1H), 7.85 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 3.24 (q, J = 6.6 Hz, 2H), 1.58 – 1.40 (m, 2H), 1.31 (q, J = 7.4 Hz, 2H), 0.89 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, DMSO- d_6) δ 165.0, 135.8, 133.4, 129.1, 128.3, 38.9, 31.2, 19.7, 13.7.

MS:m/z 211 (M⁺).

N-butyl-4-nitrobenzamide (5f)³⁰

O₂N

5f was obtained in 91% yield (101.10 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 8.15 (d, J = 8.7 Hz, 2H), 7.90 (d, J = 8.7 Hz, 2H), 7.16 (s, 1H), 3.38 (q, J = 6.7 Hz, 2H), 1.60 – 1.44 (m, 2H), 1.33 (q, J = 7.6 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 165.8, 149.3, 140.5, 128.3, 123.6, 40.2, 31.5, 20.1, 13.7. MS:m/z 222 (M⁺).

N-butyl-3-(trifluoromethyl)benzamide (5g)³¹

5g was obtained in 89% yield (109.10 mg) as a white oil;

¹H NMR (400 MHz,CDCl₃) δ 8.02 (s, 1H), 7.93 (d, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 7.7 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 1H), 6.90 (s, 1H), 3.41 (q, *J* = 7.0, 6.3 Hz, 2H), 1.57 (t, *J* = 7.6 Hz, 2H), 1.42 – 1.24 (m, 2H), 0.99 – 0.75 (m, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 166.5, 135.7, 132.8 – 131.9 (m), 131.0 (d, J = 32.7 Hz), 129.7 (d, J = 124.8 Hz), 124.4 (t, J = 54.5 Hz), 40.13, 31.65, 20.21, 13.77).

12+.0112, 12+.+(1, 3 = 5+.5112), +0.15, 51.05, 20.

¹⁹F NMR (376 MHz,CDCl₃) δ -62.80.

 $MS:m/z \ 245 \ (M^+).$

N-butyl-4-cyanobenzamide $(5h)^{32}$

5h was obtained in 92% yield (93.00 mg) as a white oil;

¹H NMR (400 MHz,CDCl₃) δ 7.85 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.15 (s, 1H), 3.34 (q, *J* = 6.8 Hz, 2H), 1.58 – 1.43 (m, 2H), 1.31 (q, *J* = 7.6 Hz, 2H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 165.9, 138.8, 132.2, 127.8, 118.1, 114.5, 40.0, 31.4, 20.1, 13.7.

MS:m/z 202 (M⁺).

4-amino-N-butylbenzamide (5i)³³

 H_0N

5i was obtained in 91% yield (87.40 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.58 (d, *J* = 8.5 Hz, 2H), 6.64 (d, *J* = 8.1 Hz, 2H), 6.08 (s, 1H), 4.00 (s, 2H), 3.40 (q, *J* = 6.7 Hz, 2H), 1.63 – 1.48 (m, 2H), 1.38 (q, *J* = 7.5 Hz, 2H), 0.93 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 167.4, 149.6, 128.6, 124.4, 114.2, 39.8, 32.0, 20.3, 14.0. MS:m/z 192 (M⁺).

MIS.III/Z 192 (IVI).

N-butyl-2-naphthamide (5j)³⁴

5j was obtained in 92% yield (104.60 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 8.62 (s, 1H), 8.45 (s, 1H), 8.07 – 8.00 (m, 1H), 7.99 – 7.91 (m, 3H), 7.68 – 7.47 (m, 2H), 3.36 – 3.25 (m, 2H), 1.55 (t, *J* = 7.0 Hz, 2H), 1.39 – 1.31 (m, 2H), 0.91 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 166.1, 134.0, 132.2, 132.1, 128.8, 127.8, 127.6, 127.4, 127.2, 126.6, 124.2, 39.0, 31.3, 19.7, 13.7.

MS:m/z 227 (M⁺).

N-butylpicolinamide (5k)³⁵

5k was obtained in 91% yield (81.10 mg) as a white oil;

¹H NMR (400 MHz, DMSO- d_6) δ 8.73 (s, 1H), 8.61 (d, J = 4.7 Hz, 1H), 8.02 (d, J = 7.7 Hz, 1H), 7.96 (t, J = 7.8 Hz, 1H), 7.56 (t, J = 6.1 Hz, 1H), 3.29 (q, J = 6.8 Hz, 2H), 1.52 – 1.46 (m, 2H), 1.28 (q, J = 7.5 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.7, 150.0, 148.3, 137.7, 126.3, 121.7, 38.4, 31.2, 19.5, 13.6. MS:m/z 178 (M⁺).

N-butylthiophene-2-carboxamide (51)³⁶



51 was obtained in 90% yield (82.50 mg) as a yellow oil;

¹H NMR (400 MHz,CDCl₃) δ 7.58 (d, *J* = 3.7 Hz, 1H), 7.41 (d, *J* = 4.9 Hz, 1H), 7.01 (d, *J* = 4.3 Hz, 1H), 6.78 (s, 1H), 3.37 (q, *J* = 6.8 Hz, 2H), 1.54 (t, *J* = 7.6 Hz, 2H), 1.33 (q, *J* = 7.4 Hz, 2H), 0.88 (t, *J* = 7.3 Hz, 3H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 162.2, 139.4, 129.8, 127.9, 127.6, 39.8, 31.7, 20.2, 13.8.

 $MS:m/z \ 183 \ (M^{+}).$

N-butyl-1H-indole-3-carboxamide (5m)³⁷



5m was obtained in 78% yield (84.40 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 10.12 (s, 1H), 7.91 (d, *J* = 6.4 Hz, 1H), 7.60 (d, *J* = 4.0 Hz, 1H), 7.40 (d, *J* = 3.8 Hz, 1H), 7.25 - 7.14 (m, 2H), 6.15 (s, 1H), 3.50 (q, *J* = 6.6 Hz, 2H), 1.68 - 1.56 (m, 2H), 1.42 (q, *J* = 7.4 Hz, 2H), 0.95 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 166.2, 136.7, 128.5, 124.6, 122.8, 121.5, 119.6, 112.5, 112.0, 39.5, 32.1, 20.4, 14.0.

MS:m/z 216 (M⁺).

N1, N3-dibutylisophthalamide $(5n)^{38}$



5n was obtained in 92% yield (127.10 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 8.54 (t, J = 5.7 Hz, 2H), 8.28 (s, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.53 (t, J = 7.7 Hz, 1H), 3.27 (q, J = 6.6 Hz, 4H), 1.55 – 1.45 (m, 4H), 1.33 (q, J = 7.5 Hz, 4H), 0.90 (t, J = 7.3 Hz, 6H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.8, 134.9, 129.5, 128.2, 126.1, 38.9, 31.2, 19.7, 13.7.

MS:m/z 276 (M⁺).

N-butyl-2-phenylacetamide (50)³⁹



50 was obtained in 90% yield (86.10 mg) as a white oil;

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.30 – 7.24 (m, 4H), 7.24 – 7.16 (m, 1H), 3.40 (s, 2H), 3.05 (q, *J* = 6.8 Hz, 2H), 1.42 – 1.32 (m, 2H), 1.30 – 1.20 (m, 2H), 0.84 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 170.4, 136.7, 129.1, 128.3, 126.5, 42.7, 38.6, 31.4, 19.7, 13.8. MS:m/z 191 (M⁺).

N-phenylacetamide $(5p)^{40}$



5p was obtained in 89% yield (60.20 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 8.41 (s, 1H), 7.41 (d, *J* = 8.0 Hz, 2H), 7.16 (t, *J* = 7.8 Hz, 2H), 6.97 (t, *J* = 7.4 Hz, 1H), 2.01 (s, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 169.3, 138.2, 128.9, 124.3, 120.3, 24.3.

MS:m/z 135 (M⁺).

N-phenylbutyramide $(5q)^{41}$



5q was obtained in 94% yield (76.70 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.99 (s, 1H), 7.50 (d, *J* = 7.9 Hz, 2H), 7.24 (t, *J* = 7.8 Hz, 2H), 7.04 (t, *J* = 7.4 Hz, 1H), 2.28 (t, *J* = 7.5 Hz, 2H), 1.69 (q, *J* = 7.5 Hz, 2H), 0.93 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 172.0, 138.2, 128.9, 124.2, 120.1, 39.6, 19.2, 13.8.

MS:m/z 163 (M⁺).

N-phenylisobutyramide $(5r)^{41}$

5r was obtained in 91% yield (74.30 mg) as a white solid;

¹H NMR (400 MHz,CDCl3) δ 8.07 (s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.17 (t, J = 7.7 Hz, 2H), 6.98 (t, J = 7.7 Hz, 2H), 7.17 (t, J =

= 7.4 Hz, 1H), 2.57 – 2.37 (m, 1H), 1.11 (d, *J* = 7.0 Hz, 6H).

¹³C NMR (100 MHz,CDCl₃) δ 176.1, 138.3, 128.8, 124.1, 120.2, 36.4, 19.6.

MS:m/z 163 (M⁺).

N-phenylcyclohexanecarboxamide $(5s)^{42}$



5s was obtained in 93% yield (94.50 mg) as a white solid;

¹H NMR (400 MHz, Chloroform-*d*) δ 7.56 (s, 1H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.18 (t, *J* = 7.9 Hz, 2H), 6.97 (t, *J* = 7.4 Hz, 1H), 2.21 – 2.08 (m, 1H), 1.87 – 1.78 (m, 2H), 1.75 – 1.64 (m, 2H), 1.62 – 1.52 (m, 1H), 1.51 – 1.36 (m, 2H), 1.23 – 1.08 (m, 4H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 174.8, 138.3, 129.0, 124.1, 120.0, 46.5, 29.7, 25.8, 25.7.

 $MS:m/z \ 203 \ (M^+).$

N-phenylpivalamide $(5t)^{43}$

5t was obtained in 90% yield (79.80 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.55 (d, J = 8.7 Hz, 2H), 7.50 (s, 1H), 7.32 (t, J = 7.8 Hz, 2H), 7.13 – 7.07 (m, 1H), 1.33 (s, 9H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 176.7, 138.1, 128.9, 124.2, 120.2, 39.6, 27.7.

MS:m/z 177 (M⁺).

(3r, 5r, 7r)-N-phenyladamantane-1-carboxamide $(5u)^{44}$

5u was obtained in 75% yield (95.80 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.54 (d, *J* = 8.0 Hz, 2H), 7.31 (t, *J* = 7.7 Hz, 3H), 7.09 (t, *J* = 7.4 Hz, 1H), 2.06 (br, 3H), 1.99 – 1.92 (m, 6H), 1.82 – 1.68 (m, 6H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 176.1, 138.2, 129.0, 124.2, 120.1, 41.6, 39.4, 36.6, 28.3.

MS:m/z 255 (M⁺).

N-phenylbenzamide $(5v)^{26}$

5v was obtained in 90% yield (88.70 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 10.28 (s, 1H), 7.97 (d, J = 7.3 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 7.61 – 7.51 (m, 3H), 7.36 (t, J = 7.8 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.6, 139.2, 135.0, 131.5, 128.6, 128.4, 127.7, 123.7, 120.4. MS:m/z 197 (M⁺).

N-phenyl-3-(trifluoromethyl)benzamide $(5w)^{45}$



5w was obtained in 84% yield (111.40 mg) as a white solid;

¹H NMR (400 MHz, DMSO- d_6) δ 10.47 (s, 1H), 8.34 – 8.21 (m, 2H), 7.95 (d, J = 7.8 Hz, 1H), 7.79 (d, J = 8.0 Hz, 3H), 7.38 (t, J = 7.8 Hz, 2H), 7.13 (t, J = 7.4 Hz, 1H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.0 , 138.8, 135.8, 131.8, 129.6, 129.3, 129.2 – 128.5 (m), 128.0 (d, J = 3.7 Hz), 125.3, 124.6 – 123.9 (m), 122.6 , 120.5.

¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -61.15.

 $MS:m/z \ 265 \ (M^+).$

3,4,5-trimethoxy-N-phenylbenzamide $(5x)^{46}$



5x was obtained in 87% (124.90 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 8.39 (s, 1H), 7.62 (d, *J* = 8.6 Hz, 2H), 7.30 (t, *J* = 7.8 Hz, 2H), 7.17 –

7.07 (m, 1H), 7.04 (s, 2H), 3.85 (s, 3H), 3.78 (s, 6H).

¹³C NMR (100 MHz,CDCl₃) δ 166.0, 153.2, 141.0, 138.1, 130.4, 129.0, 124.6, 120.6, 104.6, 60.9, 56.2. MS:m/z 287 (M⁺).

N-butylbenzothioamide (5y)⁴⁷

5y was obtained in 92% yield (88.90 mg) as a yellow oil;

¹H NMR (400 MHz, DMSO- d_6) δ 10.25 (s, 1H), 7.72 (d, J = 7.9 Hz, 2H), 7.46 (d, J = 7.1 Hz, 1H), 7.41 (t, J = 7.4 Hz, 2H), 3.69 (q, J = 6.7 Hz, 2H), 1.73 – 1.59 (m, 2H), 1.37 (q, J = 7.5 Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H).

¹³C NMR (100 MHz, DMSO-*d*₆) δ 197.0, 141.5, 130.4, 127.9, 127.2, 45.9, 29.3, 19.8, 13.8. MS:m/z 193 (M⁺).

N-butylthiophene-2-carbothioamide (5z)

5z was obtained in 88% yield (87.70 mg) as a yellow oil;

¹H NMR (400 MHz,CDCl₃) δ 7.56 (s, 1H), 7.45 (d, *J* = 4.6 Hz, 1H), 7.42 (d, *J* = 3.7 Hz, 1H), 7.06 – 6.99 (m, 1H), 3.83 – 3.70 (m, 2H), 1.71 (t, *J* = 7.5 Hz, 2H), 1.43 (q, *J* = 7.5 Hz, 2H), 0.96 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 188.6, 146.8, 132.0, 127.8, 124.5, 46.3, 30.4, 20.4, 13.9. HRMS (ESI) m/z calcd. for C₉H₁₃NS₂ [M+H]⁺: 200.0562, found 200.0571. *N-butylpyridine-2-carbothioamide* (5aa)⁴⁸

5aa was obtained in 91% yield (88.40 mg) as a yellow oil;

¹H NMR (400 MHz,CDCl₃) δ 10.12 (s, 1H), 8.63 (d, *J* = 6.9 Hz, 1H), 8.41 (d, *J* = 3.4 Hz, 1H), 7.74 (t, *J* = 7.7 Hz, 1H), 7.42 - 7.29 (m, 1H), 3.80 (q, *J* = 6.6 Hz, 2H), 1.75 - 1.61 (m, 2H), 1.41 (q, *J* = 7.5 Hz, 2H), 0.92 (t, *J* = 7.4 Hz, 3H).

 ^{13}C NMR (100 MHz,CDCl₃) δ 190.3, 151.0, 146.8, 137.1, 125.8, 124.6, 45.4, 30.0, 20.3, 13.7. MS:m/z 194 (M^+).

N-benzylethanethioamide $(5ab)^{49}$



5ab was obtained in 90% yield (74.40mg) as a yellow solid;

¹H NMR (400 MHz,CDCl₃) δ 7.85 (s, 1H), 7.35 (d, *J* = 7.0 Hz, 5H), 4.80 (d, *J* = 5.4 Hz, 2H), 2.55 (s, 3H).

¹³C NMR (100 MHz,CDCl₃) δ 200.9, 136.0, 128.9, 128.3, 128.1, 50.4, 33.9.

MS:m/z 165 (M⁺).

N-benzylcyclopropanecarbothioamide $(5ac)^{50}$



5ac was obtained in 90% yield (86.10 mg) as a yellow solid;

¹H NMR (400 MHz,CDCl₃) δ 7.65 (s, 1H), 7.13 (d, J = 7.5 Hz, 5H), 4.62 (d, J = 5.3 Hz, 2H), 1.65 (s,

1H), 1.13 – 1.06 (m, 2H), 0.72 (m, 2H).

 ^{13}C NMR (100 MHz,CDCl_3) δ 207.1, 136.2, 128.8, 128.2, 127.9, 50.1, 24.3, 12.1.

 $MS:m/z \ 191 \ (M^+).$

Manefix⁵¹

N N. H

Manefix was obtained in 87% yield (116.90 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.69 (d, *J* = 8.2 Hz, 2H), 7.37 (d, *J* = 8.3 Hz, 2H), 6.90 (s, 1H), 3.70 (t, *J* = 4.6 Hz, 4H), 3.52 (q, *J* = 5.6 Hz, 2H), 2.61 (t, *J* = 6.0 Hz, 2H), 2.51 (t, *J* = 4.6 Hz, 4H). ¹³C NMR (100 MHz,CDCl₃) δ 166.3, 137.2, 132.7, 128.5, 128.3, 66.7, 56.8, 53.2, 36.2. MS:m/z 268 (M⁺). *Fasentin*⁵²



Fasentin was obtained in 82% yield (114.60 mg) as a white oil;

¹H NMR (400 MHz,CDCl₃) δ 7.23 (d, *J* = 8.8 Hz, 1H), 6.84 (s, 1H), 6.62 (d, *J* = 7.9 Hz, 1H), 3.78 (s, 1H), 3.14 (q, *J* = 7.1 Hz, 2H), 1.26 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz,CDCl₃) δ 146.9, 132.0, 118.6, 116.2, 112.8 - 111.0 (m), 38.5, 14.6.

¹⁹F NMR (376 MHz,CDCl₃) δ -62.73.

MS:m/z 279 (M⁺).

Tubulin inhibitor⁵³



Tubulin inhibitor was obtained in 71% yield (111.30 mg) as a white solid;

¹H NMR (400 MHz,CDCl₃) δ 7.91 (1H), δ 7.20 (d, *J* = 7.4 Hz, 1H), 7.11 (s, 1H), 7.00 (t, *J* = 7.3 Hz, 1H), 6.77 (s, 2H), 4.17 – 4.05 (m, 2H), 3.88 (s, 5H), 3.84 (s, 6H), 3.11 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (100 MHz,CDCl₃) δ 168.6, 153.4, 142.5, 139.7, 132.5, 132.2, 127.3, 125.0, 124.0, 116.7 104.5, 61.0, 56.3, 50.6, 28.1. MS:m/z 313 (M⁺).

5. ¹H, ¹³C and ¹⁹F NMR spectra of products











S27





165.13	141 40 136 71 136 71 132 15 132 15 128 94 128 86 127 62	120.37	
1	1441		























¹³C NMR spectra for **3**l

165.27	159.42 157.03	141.61	135.61 135.58 131.90 128.91 127.66	122.19 122.12	115.24 115.02	
		1	YIN	Y	Y	












1 -10 -20 -30 -40 -50 -56 -70 -50 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2 11 (rps)

¹H NMR spectra for 30



¹H NMR spectra for **3p**







¹H NMR spectra for **3r**



¹³C NMR spectra for **3r**



100 90 11 (ope)

¹H NMR spectra for **3s**



¹³C NMR spectra for **3s**



100 90 11 (ope) ¹H NMR spectra for **3t**



¹³C NMR spectra for **3t**



100 90 11 (oped

¹H NMR spectra for **3u**



¹³C NMR spectra for **3u**



100 90 11 (ope)









00 190 180 170 160 150 140 130 120 110 100 9: 80 70 60 50 40 30 20 10 0 -









00 190 180 170 160 150 140 130 120 110 101 91 80 70 60 50 40 30 20 10 0 -

¹H NMR spectra for **3aa**

8.05 7.45 7.45 7.23 7.23 7.05 6.65 6.65 6.65 6.65 6.65 2.35 2.31 2.31 2.31 2.31 1.77 1.77 1.77 1.72 1.72 0.66







 $\begin{array}{c}
2.36\\
2.34\\
1.76\\
1.72\\
1.72\\
0.95\\
0.93
\end{array}$





S53





S55

















13 C NMR spectra for **5g**






























2.20 2.22 2.27 2.23 1.72 1.67 1.67 0.95 0.95 0.93





















¹H NMR spectra for 5w

8 28 8 28 8 28 7 396 7 7 196 7 7 196 7 7 7 7 15 7 15 7 15 7 15 7 15



¹³C NMR spectra for **5**w

163.98	138,78 135,80 125,80 129,63 129,63 129,63 129,63 129,63 128,05 128,05 128,05 128,05 128,05 128,05 124,27 124,24 124,24 122,60 125,60 12
1	









S82









¹³C NMR spectra for **Manefix**





¹⁹F NMR spectra for **Fasentin**



¹H NMR spectra for **Tubulin inhibitor**





¹³C NMR spectra for **Tubulin inhibitor**

168.62	153.40	142.53 139.73	132.50 132.23 127.27 125.02 124.01	116.66	104.51	61.03	56,32	50.59	28.08
			\land \land	1	I			I	1



6. References

1. Zultanski S L, Zhao J, Stahl S S. Practical synthesis of amides via copper/ABNO-catalyzed aerobic oxidative coupling of alcohols and amines[J]. Journal of the American Chemical Society, **2016**, 138(20): 6416-6419.

2. Yu P, Wang Y, Zeng Z, et al. Metal-free C–N or C–C bond cleavages of α -azido ketones: An oxidative-amidation strategy for the synthesis of α -ketothioamides and amides[J]. The Journal of Organic Chemistry, **2019**, 84(22): 14883-14891.

3. Dankers C, Tadros J, Harman D G, et al. Immobilized Carbodiimide Assisted Flow Combinatorial Protocol to Facilitate Amide Coupling and Lactamization[J]. ACS Combinatorial Science, **2020**, 22(5): 255-267.

4. Zhang R, Yao W Z, Qian L, et al. A practical and sustainable protocol for direct amidation of unactivated esters under transition-metal-free and solvent-free conditions[J]. Green Chemistry, **2021**, 23(11): 3972-3982.

5. Arisawa M, Yamaguchi M. Rhodium-catalyzed Beckmann rearrangement[J]. Organic letters, **2001**, 3(2): 311-312.

6. Sharma N, Sekar G. Stable and Reusable Binaphthyl-Supported Palladium Catalyst for Aminocarbonylation of Aryl Iodides[J]. Advanced Synthesis & Catalysis, **2016**, 358(2): 314-320.

7. Vinayak B, Chandrasekharam M. Copper-Catalyzed Direct Nitration on Aryl C–H Bonds by Concomitant Azidation–Oxidation with TMS Azide and TBHP under Aerobic Conditions[J]. Organic letters, **2017**, 19(13): 3528-3531.

8. Lei P, Wang Y, Mu Y, et al. Green-Solvent Selection for Acyl Buchwald–Hartwig Cross-Coupling of Amides (Transamidation)[J]. ACS Sustainable Chemistry & Engineering, **2021**, 9(44): 14937-14945.

9. Kim S, Kim S H, Ko H J, et al. Solution-Phase Synthesis of a Library of Biaryl Amides Using Girard's reagent T as an Acid Chloride Scavenger[J]. 대한약학회 학술대회, **2002**: 3412-3412.

10. Zheng D Z, Xiong H G, Song A X, et al. Buchwald–Hartwig amination of aryl esters and chlorides catalyzed by the dianisole-decorated Pd–NHC complex[J]. Organic & Biomolecular Chemistry, **2022**, 20(10): 2096-2101.

11. Wang X, Liu J, An G. Green synthetic method of N-arylamides using recyclable cheap metal catalyst[J]. Tetrahedron Letters, **2020**, 61(43): 152327.

12. Yamasaki R, Harada M, Nagata R, et al. Conformational switch of benzanilide derivative induced by acid; effect of pentafluorobenzoyl group[J]. The Journal of Organic Chemistry, **2022**, 87(13): 8469-8479.

13. Liu C, Chen H N, Xiao T F, et al. Organic photoredox catalyzed dealkylation/acylation of tertiary amines to access amides[J]. Chemical Communications, **2023**, 59(14): 2003-2006.

14. Song G, Sun G, Tang Y, et al. The n Bu4NI Catalysed Oxidative Benzoic Acid Amide Formation from Aryl Acetaldehydes and Amines in Aqueous Solution[J]. Journal of Chemical Research, **2013**, 37(10): 630-632.

15. Crabb T A, Soilleux S L. Microbiological transformations, part 6. Microbiological transformations of acyl derivatives of indoline, 1, 2, 3, 4-tetrahydroquinoline, 1, 2, 3, 4-tetrahydroisoquinoline and 2, 3, 4, 5-tetrahydro-1 H-1-benzazepine with the fungus Cunninghamella elegans[J]. Journal of the Chemical Society, Perkin Transactions 1, **1985**: 1381-1385.

16. Santiago A J G, Brown C A, Sommer R D, et al. Identification of key functionalization species in the Cp* Ir (III)-catalyzed-ortho halogenation of benzamides[J]. Dalton Transactions, 2020, 49(45): 16166-16174.

17. Huang J, Sun F, Liu W. Manganese-catalyzed deoxygenation of secondary and tertiary amides under mild conditions[J]. Journal of Catalysis, 2023, 423: 19-25.

18. Park J K, Shin W K, An D K. New and Efficient Synthesis of Amides from Acid Chlorides Using Diisobutyl (amino) aluminum[J]. Bull. Korean Chem. Soc, 2013, 34(5): 1592-1594.

19. Serra J, Parella T, Ribas X. Au (III)-aryl intermediates in oxidant-free C–N and C–O cross-coupling catalysis[J]. Chemical science, **2017**, 8(2): 946-952.

20. Correa A, Elmore S, Bolm C. Iron-Catalyzed N-Arylations of Amides[J]. Chemistry–A European Journal, **2008**, 14(12): 3527-3529.

21. Barragan E, Noonikara-Poyil A, Bugarin A. π -Conjugated Triazenes and Nitriles: Simple Photoinduced Synthesis of Anilides Using Mild and Metal-Free Conditions[J]. Asian Journal of Organic Chemistry, **2020**, 9(4): 593-599.

22. Sweet J S, Wang R, Manesiotis P, et al. Atropselective synthesis of N-aryl pyridones via dynamic kinetic resolution enabled by non-covalent interactions[J]. Organic & Biomolecular Chemistry, **2022**, 20(12): 2392-2396.

23. Hodgkinson J T, Galloway W R J D, Wright M, et al. Design, synthesis and biological evaluation of non-natural modulators of quorum sensing in Pseudomonas aeruginosa[J]. Organic & Biomolecular Chemistry, **2012**, 10(30): 6032-6044.

24. Wang L, Lu C, Yue Y, et al. Visible-light-promoted oxo-sulfonylation of ynamides with sulfonic acids[J]. Organic letters, **2019**, 21(10): 3514-3517.

25. Schoepf A M, Salcher S, Obexer P, et al. Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators[J]. European Journal of Medicinal Chemistry, **2020**, 185: 111748.

26. Vijayasankar A V, Kathyayini H, Tumma H, et al. Mesoporous Iron Aluminophosphate: An Efficient Catalyst for One Pot Synthesis of Amides by Ester-Amide Exchange Reaction[J]. Advances in Inorganic Phosphate Materials: Ceramic Transactions, **2012**, 233: 127-140.

27. Maj A, Kudelko A, Świątkowski M. Novel Conjugated s-Tetrazine Derivatives Bearing a 4 H-1, 2,
4-Triazole Scaffold: Synthesis and Luminescent Properties[J]. Molecules, 2022, 27(2): 459.

28. Silva R H N, Machado T Q, da Fonseca A C C, et al. Molecular Modeling and In Vitro Evaluation of Piplartine Analogs against Oral Squamous Cell Carcinoma[J]. Molecules, **2023**, 28(4): 1675.

29. Chen H, Xu X, Liu L L, et al. Phosphorus oxychloride as an efficient coupling reagent for the synthesis of esters, amides and peptides under mild conditions[J]. RSC advances, **2013**, 3(37): 16247-16250.

30. Mamidi N, Manna D. Zn (OTf) 2-promoted chemoselective esterification of hydroxyl group bearing carboxylic acids[J]. The Journal of Organic Chemistry, **2013**, 78(6): 2386-2396.

31. Whittaker A M, Dong V M. Nickel-Catalyzed Dehydrogenative Cross-Coupling: Direct Transformation of Aldehydes into Esters and Amides[J]. Angewandte Chemie International Edition, **2015**, 54(4): 1312-1315.

32. Lynch K R, Kharel Y, Santos W L, et al. Inhibitors of spinster homolog 2 (spns2) for use in therapy: U.S. Patent Application 17/310,179[P]. **2022**-3-24.

33. Le P, Kunold E, Macsics R, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms[J]. Nature chemistry, **2020**, 12(2): 145-158.

34. Arkaitz C, Ruben M. Ni-Catalyzed Direct Reductive Amidation via C–O Bond Cleavage[J]. 2014.35. Guo Z, Dowdy E D, Li W S, et al. A novel method for the mild and selective amidation of diesters

and the amidation of monoesters[J]. Tetrahedron Letters, 2001, 42(10): 1843-1845.

36. Buchstaller H P, Ebert H M, Anlauf U. Efficient procedure for the preparation of amides using polymer-bound reagents[J]. Synthetic Communications, **2001**, 31(7): 1001-1005.

37. Ito Y, Kobayashi K, Takeo S. Reactions of o-tolyl isocyanide with isocyanate and isothiocyanate syntheses of n-substituted indole-3-carboxamides and indole-3-thiocarboxamides[J]. Tetrahedron Letters, **1979**, 20(12): 1039-1042.

38. Kinsella M, Duggan P G, Muldoon J, et al. Synthesis and NMR Binding Studies towards Rational Design of a Series of Electron-Withdrawing Diamide Receptors/Organocatalysts[J]. **2011**.

39. Ramesh P, Fadnavis N W. Ammonium nitrate: A biodegradable and efficient catalyst for the direct amidation of esters under solvent-free conditions[J]. Chemistry Letters, **2015**, 44(2): 138-140.

40. Jiang H, Hu Z, Gan C, et al. Visible-light induced one-pot hydrogenation and amidation of nitroaromatics with carboxylic acids over 2D MXene-derived Pt/N-TiO2/Ti3C2[J]. Molecular Catalysis, **2021**, 504: 111490.

41. Zhang L, Wang W, Wang A, et al. Aerobic oxidative coupling of alcohols and amines over Au–Pd/resin in water: Au/Pd molar ratios switch the reaction pathways to amides or imines[J]. Green chemistry, **2013**, 15(10): 2680-2684.

42. Kang S, Yim H, Won J, et al. Effective Amidation of Carboxylic Acids Using (4, 5-Dichloro-6-oxo-6H-pyridazin-1-yl)-phosphoric Acid Diethyl Ester[J]. BULLETIN-KOREAN CHEMICAL SOCIETY, **2008**, 29(5): 1025.

43. Caiuby C A D, de Jesus M P, Burtoloso A C B. α -Imino iridium carbenes from imidoyl sulfoxonium ylides: application in the one-step synthesis of indoles[J]. The Journal of Organic Chemistry, **2020**, 85(11): 7433-7445.

44. Zuo D, Wang Q, Liu L, et al. Highly Chemoselective Transamidation of Unactivated Tertiary Amides by Electrophilic N– C (O) Activation by Amide-to-Acyl Iodide Re-routing[J]. Angewandte Chemie International Edition, **2022**, 61(24): e202202794.

45. Xiong N, Dong Y, Xu B, et al. Mild Amide Synthesis Using Nitrobenzene under Neutral Conditions[J]. Organic Letters, **2022**, 24(26): 4766-4771.

46. Azeez S, Sureshbabu P, Sabiah S, et al. Controlled reduction of activated primary and secondary amides into aldehydes with diisobutylaluminum hydride[J]. Organic & Biomolecular Chemistry, **2022**, 20(10): 2048-2053.

47. Yang C H, Li G J, Gong C J, et al. N, N-Dialkylaniline-assisted thionation of carboxylic amides and esters[J]. Tetrahedron, **2015**, 71(4): 637-642.

48. Ramachandran K L. Synthesis and Characterization of 2-and 4-Substitued Pyridine Carbothionamides and 2-and 4-Pyridinethio Carbonyl Ureas[J]. Asian Journal of Chemistry, **2005**, 17(3): 1559.

49. Sheng H, Zeng R, Wang W, et al. An Efficient Heterobimetallic Lanthanide Alkoxide Catalyst for Transamidation of Amides under Solvent-Free Conditions[J]. Advanced Synthesis & Catalysis, **2017**, 359(2): 302-313.

50. Charette A B, Grenon M. Mild method for the conversion of amides to thioamides[J]. The Journal of Organic Chemistry, **2003**, 68(14): 5792-5794.

51. Li G, Ji C L, Hong X, et al. Highly chemoselective, transition-metal-free transamidation of unactivated amides and direct amidation of alkyl esters by N–C/O–C cleavage[J]. Journal of the American Chemical Society, **2019**, 141(28): 11161-11172.

52. Tang J, Huber A D, Pineda D L, et al. 5-Aminothiophene-2, 4-dicarboxamide analogues as hepatitis

B virus capsid assembly effectors[J]. European journal of medicinal chemistry, 2019, 164: 179-192.
53. Niggli N E, Vollgraff T, Winter C, et al. Synthesis of Anilides by Aminolysis of Unactivated Esters using MnCl2 in Combination with strong Bases as Catalyst[J]. Advanced Synthesis & Catalysis, 2023, 365(11): 1794-1800.